Immune checkpoint inhibitors (ICIs) are considered a new standard-of-care across many
cancer indications. This review provides an update on ICIs approved by the Food and Drug …

Triple negative breast cancer (TNBC) is a subtype of breast cancer, with estrogen receptor,
human epidermal growth factor receptor 2 and progesterone receptor negative. TNBC is …

Breast cancer is the most prevalent type of cancer among women. Several types of drugs,
targeting the specific proteins expressed on the breast cancer cell surface (such as receptor …

Both angiogenesis and lncRNAs play crucial roles in the development and progression of
breast cancer. Considering the unknown association of angiogenesis and lncRNAs in breast …

A lack of therapeutically targetable molecular alterations and its aggressive nature make
triple-negative breast cancer [TNBC] a challenging disease. Chemotherapy is standard of …

Triple-negative breast cancer (TNBC) remains a most deadly human malignancy with limited
response to chemotherapy, targeted therapy and immunotherapy. Tumor …

Triple-negative breast cancer (TNBC) is an aggressive malignancy for which cytotoxic
chemotherapy remains the backbone of treatment. Trilaciclib is an intravenous cyclin …

Background: To classify triple-negative breast cancer (TNBC) immunotyping using the public
database, analyze the differences between subtypes in terms of clinical characteristics and …

Combination immunotherapy has emerged as a promising strategy to address the
challenges associated with immune checkpoint inhibitor (ICI) therapy in breast cancer. The …

Simple Summary Hepatocellular carcinoma (HCC) is one of the most malignant tumors.
Immune checkpoint inhibitors (ICIs)-based therapy has recently been demonstrated to …